The result of nearly a decade of research and development, CytImmune scientists have engineered a variety of new nano-scale drug entities, formulating the optimal structures for binding potent anti-cancer agents which synergize with TNF’s biological actions to its core platform.
To preserve the commercial value of CytImmune’s product pipeline, each successive development program builds upon previous discoveries and attacks cancer with unique mechanisms of action.
CytImmune’s lead clinical compound, Aurimune (CYT-6091), and earlier stage candidates have the potential to be used in multiple types of solid tumors -- either as monotherapies or in combination with existing standards of care -- as its therapies are independent of tumor specific biochemistry and, therefore, do not depend on the type of cancer treated.
CytImmuneintends to bring Aurimune(CYT-6091) and earlier stage drug candidates through the FDA regulatory process and enter into strategic relationships with major pharmaceutical companies for territories outside North America. The Company has more than 60 issued and pending patents for its colloidal gold nanotechnology and 11 issued and pending patents for its mAb technology in the US, EU, Japan and Canada.
If approved for use, the market potential for CytImmune’s compounds is significant; as they not only treat the acute illness, but also once under control, shift the treatment paradigm to managing cancer as a chronic disease with little or no impact on quality of life.
CytImmune retains worldwide commercialization rights for its drug candidates. Current human drug candidates include CYT-6091, (Aurimune) Pegylated Colloidal Gold bound TNF; CYT-21001, (AuriTol) Pegylated Colloidal Gold bound TNF with Paclitaxel; CYT-31000, (AuriCin) Pegylated Colloidal Gold bound TNF with Doxorubicin; CYT-41000, Pegylated Colloidal Gold bound TNF with Interleukin-12; CYT-51000, Pegylated Colloidal Gold bound TNF with Interleukin-2.